CSI Market
Sign In | Register

Coherus Oncology inc (CHRS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CHRS Annual Cash Flow →
Reviewing cash flow figures over time highlights how Coherus Oncology inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-58.96
Depreciation & amortization1.74
Amortization of Other Assets1.30
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories10.88
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges0.00
Share-based Compensation4.97
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Fair Value Of Warrants In Excess Of Debt Proceeds Recognized At Issuance-
Fair Value Of Embedded Derivatives In Excess Of Debt Proceeds Recognized At Issuance-
Increase Decrease In Advance Payments Under License Agreement-
Non Cash Bonus Payment Settled In Common Stock-
Excess And Obsolete Inventory-
Non Cash Operating Lease Expense-
Increase Decrease In Accrued Rebates Fees And Returns-
Increase Decrease In Accrued Compensation0.03
Upfront License Fee Payments Related To License And Collaboration Arrangements-
Impairment Of Intangible Assets And Contingent Value Rights Liability-
Gain Loss On Sale Of Interest In Projects0.39
Change In Fair Value Of Derivatives-
Increase Decrease In Accrued Rebates Fees And Reserve-1.63
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables-3.94
Increase (Decrease) in Accounts Payable, Trade4.25
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-8.45
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-4.57
Other Working Capital42.17
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-120.70
Discontinued operations11.32
Net Cash flow from Operating Activities-119.98
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities81.67
Payments to Acquire Marketable Securities-20.29
Real Estate Investments0.00
Payments To Acquire Interest In Related Party-
Upfront And Milestone Payments Related To License And Collaboration Arrangements-
Upfront And Milestone Based License Fee Payments Investing Activities-
Payments For Milestone Based License Fee-
Increase in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-1.10
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities60.29
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.12
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock53.85
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Follow On Offering Net Of Underwriters Discounts And Commissions-
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts And Commissions-
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs-
Payments To Acquire Capped Call Options Related To Convertible Debt-
Finance Lease Principal Payments-
Proceeds From Revenue Purchase And Sale Agreement Net-
Proceeds From Repayments Of Revenue Purchase And Sale Agreement Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities53.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-119.98
Total Cash Flow-5.96
4 historic quarters locked

Sign in to unlock the full Coherus Oncology inc cash flow history.

Sign In Create Free Account

About Coherus Oncology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-091262

Figures are derived from filed reports and may be restated. Historical data is subject to revision.